Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

603087 Gan&Lee Pharmaceuticals.

Closed 03-13 15:00:00

62.13

-0.49

-0.78%

High62.72	Low61.88	Vol3.41M
Open62.24	D1 Closing62.62	Amplitude1.34%
Mkt Cap37.09B	Tradable Cap34.67B	Total Shares597.00M
T/O213.00M	T/O Rate0.61%	Tradable Shares558.00M
P/B3.29	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"Gan&Lee Pharmaceuticals.","latestPrice":62.13,"timestamp":1773385201000,"preClose":62.62,"halted":0,"volume":3414245,"delay":0,"changeRate":-0.0078,"floatShares":558000000,"shares":597000000,"eps":1.5499,"marketStatus":"Closed","change":-0.49,"latestTime":"03-13 15:00:00","open":62.24,"high":62.72,"low":61.88,"amount":213000000,"amplitude":0.0134,"askPrice":62.13,"askSize":39,"bidPrice":62.12,"bidSize":7,"shortable":0,"etf":0,"ttmEps":1.5499,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":5,"adr":0,"adjPreClose":62.62,"symbolType":"stock","openAndCloseTimeList":[[1773365400000,1773372600000],[1773378000000,1773385200000]],"highLimit":68.88,"lowLimit":56.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.29,"roa":"--","peRate":40.086457,"roe":"7.21%","epsLYR":1.04,"committee":0.253406,"marketValue":37111000000,"turnoverRate":0.0061,"status":1,"floatMarketCap":34660000000},"requestUrl":"/m/hq/s/603087/wiki","defaultTab":"wiki","newsList":[{"id":"2616348506","title":"Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2616348506","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616348506?lang=en_us&edition=fundamental","pubTime":"2026-03-03 17:15","pubTimestamp":1772529331,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  obtained the approval of China's drug regulator to conduct clinical trials for GLR2037 tablets to treat advanced prostate cancer.The investigational therapy utilizes novel protein degradation technology to target androgen receptors, according to a Tuesday filing with the Shanghai bourse.Shares of the company were down 3% Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"1169160645","title":"Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1169160645","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169160645?lang=en_us&edition=fundamental","pubTime":"2026-03-03 13:21","pubTimestamp":1772515309,"startTime":"0","endTime":"0","summary":"On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"gpt_icon":0},{"id":"1121012946","title":"Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1121012946","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121012946?lang=en_us&edition=fundamental","pubTime":"2026-03-02 18:12","pubTimestamp":1772446337,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2605745651","title":"Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605745651","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605745651?lang=en_us&edition=fundamental","pubTime":"2026-01-22 11:27","pubTimestamp":1769052468,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  expects its net profit attributable to shareholders in 2025 to jump between 79% and 95% year on year to 1.10 billion yuan and 1.20 billion yuan, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's attributable profit a year earlier was 614.7 million yuan or 1.04 yuan per share.The company's shares slipped nearly 2% during the morning trade Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"1194687370","title":"Gan & Lee Pharmaceuticals (603087.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Owners to Increase 78.96% to 95.23% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1194687370","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194687370?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:39","pubTimestamp":1768995577,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) has released its 2025 annual performance forecast, anticipating a net profit attributable to owners of the parent company in the range of 1.10 billion to 1.20...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"gpt_icon":0},{"id":"1182448230","title":"Gan & Lee Pharmaceuticals (603087.SH): Insulin Glargine Injection and Its Pre-filled Pen Receive Drug Registration Approval in Ethiopia","url":"https://stock-news.laohu8.com/highlight/detail?id=1182448230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182448230?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:08","pubTimestamp":1768482494,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) announced that it has recently received drug registration approvals for its Insulin Glargine Injection and Insulin Glargine Injection Pre-filled Pen from the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2603784606","title":"Gan & Lee Pharmaceuticals Gets EU Approval for Insulin Injection; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603784606","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603784606?lang=en_us&edition=fundamental","pubTime":"2026-01-15 13:04","pubTimestamp":1768453478,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  obtained marketing authorization from the European Commission for its insulin glargine injection  for the European Union, Iceland, Liechtenstein and Norway.The long-acting insulin is administered via subcutaneous injection once daily to treat diabetes, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 4% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239","BK4156"],"gpt_icon":0},{"id":"2603988697","title":"Sandoz Receives European Commission Approval for Ondibta Insulin Glargine","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603988697?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:01","pubTimestamp":1768388513,"startTime":"0","endTime":"0","summary":"Sandoz Group AG has received marketing authorization from the European Commission for Ondibta , a biosimilar developed and registered by Gan & Lee Pharmaceuticals. Ondibta is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, with demonstrated equivalence to the reference medicine, Lantus SoloStar, in terms of safety, quality, and efficacy. The product is expected to launch by early 2027, with the potential to expand access to insulin treatment options for patients across Europe. Under a commercialization agreement, Sandoz will market Ondibta in Europe and other key territories, while Gan & Lee is responsible for development, registration, manufacturing, and supply.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL7dszyy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"gpt_icon":0},{"id":"1151806570","title":"Gan & Lee Pharmaceuticals Dismisses CFO and Vice President","url":"https://stock-news.laohu8.com/highlight/detail?id=1151806570","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151806570?lang=en_us&edition=fundamental","pubTime":"2026-01-04 19:31","pubTimestamp":1767526263,"startTime":"0","endTime":"0","summary":"On the evening of December 31, Gan & Lee Pharmaceuticals announced the dismissal of its Chief Financial Officer and Vice President, Sun Cheng, citing strategic needs for the globalization upgrade of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2600037625","title":"Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2600037625","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600037625?lang=en_us&edition=fundamental","pubTime":"2026-01-02 09:24","pubTimestamp":1767317073,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  has removed Sun Cheng from his positions as chief financial officer and vice general manager, according to a Thursday filing with the Shanghai Stock Exchange.The company said Sun's dismissal is a \"strategic measure\" designed to \"optimize and adjust senior management personnel based on the company's strategic need for global upgrading of its innovative drug R&D, marketing, and investment and financing businesses.\"The Chinese pharmaceutical company subsequently appointed Zhou Li as acting CFO, effective immediately, until a new CFO is appointed.Zhou joined Gan & Lee's finance department in 2012 and has served as the director of the company's finance department since October 2019.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2595275059","title":"INDIA STOCKS-Indian equity benchmarks eye muted start on persistent foreign outflows","url":"https://stock-news.laohu8.com/highlight/detail?id=2595275059","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595275059?lang=en_us&edition=fundamental","pubTime":"2025-12-30 10:38","pubTimestamp":1767062321,"startTime":"0","endTime":"0","summary":"INDIA STOCKS-Indian equity benchmarks eye muted start on persistent foreign outflows Dec 30 (Reuters) - India's equity benchmarks are likely to open little changed on Tuesday, as investors remained ca","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nL4N3Y0036:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2590604983","title":"Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2590604983","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590604983?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:18","pubTimestamp":1765243081,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  has secured approval from China's National Medical Products Administration to carry out clinical trials for its investigational drug, GLR1044 injection, according to a Shanghai Stock Exchange filing on Tuesday.The drug is indicated to treat moderate to severe atopic dermatitis in adults who have inadequate control with, or are not suitable for, topical prescription drugs.GLR1044 injection is a biosimilar of Dupilumab, a drug currently marketed in China only by the original manufacturer, Sanofi, under the brand name Dapoxetine, the company said.Global sales of Dapoxetine reached 13 billion euros in 2024, Gan & Lee noted, citing data from Sanofi.The company has spent 66 million yuan in GLR1044's research and development as of Sept. 30.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2586243878","title":"Once-Monthly Glp-1 Ra | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (Gradual-3) of the First Chinese Once-Monthly Glp-1 Ra for Weight Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2586243878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586243878?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:50","pubTimestamp":1764233414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nTUA5TQBQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"1138804397","title":"Gan&Lee Pharmaceuticals: Business Operations Remain Normal","url":"https://stock-news.laohu8.com/highlight/detail?id=1138804397","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138804397?lang=en_us&edition=fundamental","pubTime":"2025-11-26 23:10","pubTimestamp":1764169852,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals stated on November 26 in response to investor inquiries that its business operations remain normal. In the first three quarters of 2025, the company reported revenue of 3.047...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"gpt_icon":0},{"id":"1189004134","title":"Gan&Lee Pharmaceuticals (603087.SH): CHMP Grants Positive Opinion for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta®) in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1189004134","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189004134?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:20","pubTimestamp":1763025640,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals (603087.SH) announced that the company and its wholly-owned European subsidiary, Gan&Lee Pharmaceuticals Europe GmbH, recently received notification from the European...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK4087","FESXmain","FSXEmain","CHMP","BK4215","603087","MAA","BK4588","BK4585"],"gpt_icon":0},{"id":"2569727671","title":"BUZZ-China's Gan & Lee Pharma jumps most in 5 months on Biomm tie-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2569727671","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569727671?lang=en_us&edition=fundamental","pubTime":"2025-09-24 13:52","pubTimestamp":1758693151,"startTime":"0","endTime":"0","summary":"BUZZ-China's Gan & Lee Pharma jumps most in 5 months on Biomm tie-up** Shares of Gan & Lee Pharmaceuticals 603087.SS jump 10% to 79.34 yuan, on course for biggest one-day pct rise since April 25** The China-based insulin analog injections producer says it has signed supply framework agreement with Biomm valued at least 3 bln yuan ** Benchmark CSI 300 Index .CSI300 and Shanghai SE Composite Index .SSEC both up 0.6%** YTD, stock up 79.9%, CSI Health Care 100 Index .CSI000978 up 14.8%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nL2N3VB04H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"gpt_icon":0},{"id":"1103374180","title":"3 Billion Yuan Deal! Gan & Lee Pharmaceuticals Hits Daily Limit, Drug ETF (562050) Surges Over 1%! Hong Kong Stock Connect Innovative Drug Leaders Gain Momentum, 520880 Premium Turns Positive","url":"https://stock-news.laohu8.com/highlight/detail?id=1103374180","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103374180?lang=en_us&edition=fundamental","pubTime":"2025-09-24 10:50","pubTimestamp":1758682255,"startTime":"0","endTime":"0","summary":"On Wednesday morning (September 24), AH pharmaceutical sectors showed divergent performance. A-share pharmaceutical sector recovered, with innovative drugs and traditional Chinese medicine rising...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159992","06978","HSCEI","BK1161","562050","BK0239","HSTECH","BK4614","603087","07226","YANG"],"gpt_icon":1},{"id":"2569879217","title":"Gan & Lee Pharmaceuticals  Says It Signed Supply Framework Agreement With Biomm Worth Expected at Least 3 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2569879217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569879217?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:32","pubTimestamp":1758627136,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nL3N3VA0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2569792177","title":"BRIEF-Gan & Lee Pharmaceuticals Signs Framework Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2569792177","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569792177?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:32","pubTimestamp":1758627136,"startTime":"0","endTime":"0","summary":"BRIEF-Gan & Lee Pharmaceuticals Signs Framework AgreementSept 23  - Gan & Lee Pharmaceuticals 603087.SS:SAYS IT SIGNED SUPPLY FRAMEWORK AGREEMENT WITH BIOMM WORTH EXPECTED AT LEAST 3 BILLION YUAN Source textFurther company coverage: 603087.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nL3N3VA0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","stockEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0552},{"period":"6month","weight":-0.1555},{"period":"1year","weight":0.3619},{"period":"ytd","weight":-0.0801}],"companyName":"甘李药业股份有限公司","boardCode":"AI0027","perCapita":"5889股","boardName":"医药制造业","registeredCapital":"59730万元","compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0002},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.0668},{"period":"1year","weight":0.2246},{"period":"ytd","weight":0.0404}],"survey":"　　甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。","serverTime":1773401454108,"listedPrice":63.32,"stockholders":"94714人(较上一季度增加22.53%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gan&Lee Pharmaceuticals.,603087,Gan&Lee Pharmaceuticals.股票,Gan&Lee Pharmaceuticals.股票老虎,Gan&Lee Pharmaceuticals.股票老虎国际,Gan&Lee Pharmaceuticals.行情,Gan&Lee Pharmaceuticals.股票行情,Gan&Lee Pharmaceuticals.股价,Gan&Lee Pharmaceuticals.股市,Gan&Lee Pharmaceuticals.股票价格,Gan&Lee Pharmaceuticals.股票交易,Gan&Lee Pharmaceuticals.股票购买,Gan&Lee Pharmaceuticals.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction